Evotaz Side Effects
Generic Name: atazanavir / cobicistat
Note: This document contains side effect information about atazanavir / cobicistat. Some of the dosage forms listed on this page may not apply to the brand name Evotaz.
More frequent side effects include: first degree atrioventricular block. See below for a comprehensive list of adverse effects.
For the Consumer
Applies to atazanavir / cobicistat: oral tablet, tablet oral
Check with your doctor immediately if any of the following side effects occur while taking atazanavir / cobicistat:More common
- Abdominal or stomach pain
- clay-colored stools
- dark urine
- itching or rash
- loss of appetite
- unpleasant breath odor
- unusual tiredness or weakness
- vomiting of blood
- yellow eyes or skin
- Abdominal or stomach fullness or tenderness
- black, tarry stools
- blistering, peeling, or loosening of the skin
- blood in the urine
- chest pain
- clay colored stools
- decreased appetite
- gaseous abdominal or stomach pain
- joint or muscle pain
- pain in the groin or genitals
- painful or difficult urination
- recurrent fever
- red skin lesions, often with a purple center
- red, irritated eyes
- sharp back pain just below the ribs
- sore throat
- sores, ulcers, or white spots in the mouth or on the lips
- swelling of the feet or lower legs
- swollen glands
- unusual bleeding or bruising
For Healthcare Professionals
Applies to atazanavir / cobicistat: oral tablet
In clinical trials, safety of this drug was evaluated in HIV-1-infected, antiretroviral therapy-naive patients using the individual components with other antiretrovirals for at least 48 weeks. In 1 trial, atazanavir and cobicistat were used with emtricitabine-tenofovir (cobicistat-boosted group); in another trial, atazanavir and ritonavir were used with emtricitabine-tenofovir (ritonavir-boosted group). In the cobicistat-boosted group, the most common side effects were jaundice, ocular icterus, and nausea; in the ritonavir-boosted group, the most common side effects were jaundice, ocular icterus, nausea, and diarrhea. Study treatment was discontinued due to side effects in 7% of patients in both the cobicistat- and the ritonavir-boosted groups. Most of the side effects included from clinical trials were of at least moderate intensity (grade 2 or higher).
The manufacturer product information for atazanavir and cobicistat should be consulted for additional safety information.[Ref]
Increases in total bilirubin greater than 2.5 times the upper limit of normal (2.5 x ULN) was reported in 65% of patients in the cobicistat-boosted group and 56% in the ritonavir-boosted group. Increased ALT (greater than 5 x ULN), AST (greater than 5 x ULN), and GGT (greater than 5 x ULN) were reported in 3%, 3%, and 2% of patients in the cobicistat-boosted group, respectively, and 2%, 2%, and 1% of patients in the ritonavir-boosted group, respectively.
Jaundice was reported in the cobicistat-boosted group (all grades: 13%; grades 2 to 4: 5%) and the ritonavir-boosted group (all grades: 11%; grades 2 to 4: 3%).
Most patients taking atazanavir experienced asymptomatic elevations in indirect (unconjugated) bilirubin related to inhibition of UGT. This hyperbilirubinemia was reversible upon discontinuation of atazanavir.[Ref]
Very common (10% or more): Increased total bilirubin (65%), jaundice (up to 13%)
Common (1% to 10%): Increased ALT, increased AST, increased GGT
-Very common (10% or more): Elevated indirect (unconjugated) bilirubin/hyperbilirubinemia, UDP-glucuronosyl transferase (UGT) inhibited, jaundice, increased total bilirubin
-Common (1% to 10%): Increased ALT, increased AST, increased GGT
-Postmarketing reports: Hepatic function abnormalities, cholelithiasis, cholecystitis, cholestasis[Ref]
Ocular icterus was reported in the cobicistat-boosted group (all grades: 15%; grades 2 to 4: 3%) and the ritonavir-boosted group (all grades: 17%; grades 2 to 4: 1%).[Ref]
Very common (10% or more): Ocular icterus (up to 15%)
-Very common (10% or more): Ocular icterus[Ref]
Very common (10% or more): Nausea (up to 12%)
Common (1% to 10%): Increased lipase, increased serum amylase
Frequency not reported: Diarrhea, vomiting, upper abdominal pain
-Very common (10% or more): Nausea, diarrhea
-Common (1% to 10%): Increased lipase, increased serum amylase
-Postmarketing reports: Pancreatitis[Ref]
Nausea was reported in the cobicistat-boosted group (all grades: 12%; grades 2 to 4: 2%) and the ritonavir-boosted group (all grades: 11%; grades 2 to 4: 2%). Diarrhea (all grades) was reported in 11% of patients in the ritonavir-boosted group.
Increased serum amylase (greater than 2 x ULN) was reported in 4% and 2% of patients in the cobicistat-boosted and ritonavir-boosted groups, respectively.
If serum amylase was greater than 1.5 x ULN, lipase was also measured. Increased lipase (grades 3 to 4) was reported in 9% and 6% of patients in the cobicistat-boosted and ritonavir-boosted groups, respectively.[Ref]
Common (1% to 10%): Rash (rash events included allergic dermatitis, drug hypersensitivity, generalized pruritus, eosinophilic pustular folliculitis, rash, generalized rash, macular rash, maculopapular rash, morbilliform rash, papular rash, urticaria)
-Common (1% to 10%): Rash events
-Frequency not reported: Stevens-Johnson syndrome, erythema multiforme, toxic skin eruptions, drug rash with eosinophilia and systemic symptoms (DRESS) syndrome, mild-to-moderate maculopapular skin eruptions
-Postmarketing reports: Alopecia, maculopapular rash, pruritus, angioedema[Ref]
Rash events (grades 2 to 4) were reported in 5% and 4% of patients in the cobicistat-boosted and ritonavir-boosted groups, respectively.[Ref]
Increased creatine kinase (at least 10 x ULN) was reported in 5% and 6% of patients in the cobicistat-boosted and ritonavir-boosted groups, respectively.[Ref]
Nephrolithiasis has been reported with atazanavir. In clinical trials, nephrolithiasis was reported in 2% of patients in the cobicistat-boosted group and no patients in the ritonavir-boosted group. Onset of nephrolithiasis was about 24 weeks in the cobicistat-boosted group.
In clinical trials, serum creatinine increased and estimated CrCl decreases occurred early during therapy in the cobicistat-boosted group after which they stabilized. After 48 weeks of therapy, eGFR (based on CrCl) change averaged -13.4 mL/min in the cobicistat-boosted group and -9.1 mL/min in the ritonavir-boosted group.
Renal impairment (including acute renal failure and Fanconi syndrome) has been reported when cobicistat was used in a regimen containing tenofovir.
In clinical trials over 48 weeks (n=771), 6 (1.5%) patients using atazanavir, cobicistat, and tenofovir discontinued therapy due to a renal side effect; 5 patients had laboratory findings consistent with proximal renal tubulopathy. None of the 5 patients had baseline renal dysfunction (e.g., estimated CrCl less than 70 mL/min). Laboratory findings in these 5 patients improved but did not completely resolve in all patients when therapy was stopped. No patients required renal replacement therapy.[Ref]
Common (1% to 10%): Nephrolithiasis
Frequency not reported: Decreased estimated CrCl, increased serum creatinine, decreased estimated glomerular filtration rate (eGFR; based on CrCl), nephropathy, Fanconi syndrome, laboratory findings consistent with proximal renal tubulopathy
-Frequency not reported: Decreased eGFR
-Postmarketing reports: Nephrolithiasis, interstitial nephritis
-Frequency not reported: Decreased estimated CrCl, increased serum creatinine, tubular secretion of creatinine inhibited (actual renal glomerular function not affected), decreased eGFR, renal impairment (including acute renal failure, Fanconi syndrome)[Ref]
Increased urine RBC (greater than 75 RBC/high power field) and urine glucose (at least 1000 mg/dL) have been reported in 3% and 3% of patients in the cobicistat-boosted group, respectively, and 2% and 1% of patients in the ritonavir-boosted group, respectively.[Ref]
Frequency not reported: Increased fasted total cholesterol, increased fasted high-density lipoprotein cholesterol, increased fasted low-density lipoprotein cholesterol, increased fasted triglycerides
-Postmarketing reports: New onset diabetes mellitus, exacerbation of preexisting diabetes mellitus, hyperglycemia, diabetic ketoacidosis
Combination antiretroviral therapy:
-Frequency not reported: Redistribution/accumulation of body fat (including central obesity, dorsocervical fat enlargement, peripheral wasting, facial wasting, breast enlargement, "cushingoid appearance")[Ref]
Frequency not reported: Headache[Ref]
-Common (1% to 10%): First-degree atrioventricular (AV) block
-Frequency not reported: Prolongation of the PR interval, abnormalities in AV conduction, other conduction abnormalities
-Postmarketing reports: Second-degree AV block, third-degree AV block, left bundle branch block, QTc prolongation[Ref]
-Frequency not reported: Immune reconstitution syndrome
Combination antiretroviral therapy:
-Frequency not reported: Immune reconstitution syndrome, autoimmune disorders in the setting of immune reconstitution (e.g., Graves' disease, polymyositis, Guillain-Barre syndrome)[Ref]
Protease inhibitor therapy:
-Frequency not reported: Increased bleeding (including spontaneous skin hematomas, hemarthrosis) in hemophiliacs[Ref]
1. "Product Information. Evotaz (atazanavir-cobicistat)." Bristol-Myers Squibb, Princeton, NJ.
2. "Product Information. Reyataz (atazanavir)." Bristol-Myers Squibb, Princeton, NJ.
Some side effects of Evotaz may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.
More about Evotaz (atazanavir / cobicistat)
- Side Effects
- During Pregnancy
- Dosage Information
- Drug Images
- Drug Interactions
- Support Group
- Pricing & Coupons
- En Español
- 0 Reviews – Add your own review/rating
- Drug class: antiviral combinations
Related treatment guides
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.